Pharma, Biotech and Generics Industry News | The Pharmaletter
2024年10月15日 · India unleashes Bio-RIDE to spur biotech growth and innovation. 7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. Pharmaceutical.
Pharma and Biotech News | The Pharmaletter
6 天之前 · PharmaMar releases top-line data on Zepzelca and Tecentriq combo in lung cancer. Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024.
Pharma and Biotech Insights | The Pharmaletter
2024年10月2日 · NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024.
FDA drug regulation and approval news | The Pharmaletter
2024年10月8日 · FDA grants full approval for Retevmo in MTC. The US Food and Drug Administration (FDA) granted traditional approval for US pharma major Eli Lilly’s Retevmo (selpercatinib) for adult and pediatric patients two years and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. 30 September 2024. Biotechnology.
Pharmaceutical Industry News | The Pharmaletter
2024年10月9日 · Exclusive. Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food ...
Pharmaceutical Generics Industry News | The Pharmaletter
2024年9月5日 · Glenmark pays $25 million fine for generic price-fixing. Glenmark Pharmaceuticals has agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug, the US Department of Justice announced. 5 September 2024. More Generics News >.
Pharma and Biotech Diabetes News | The Pharmaletter
2024年10月10日 · Eli Lilly has announced positive results from two Phase III trials evaluating its once-weekly insulin efsitora alfa (efsitora) against the daily insulin degludec for adults with type 1 and type 2 diabetes.
Pharma M&A news | The Pharmaletter
2024年10月5日 · Fosun Pharma secures full ownership of Fosun Kite with $27 million deal. Shanghai-based Fosun Pharmaceutical has announced it has acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 million, giving it full control of the joint venture. 23 September 2024. Pharmaceutical.
The week in pharma: action, reaction and insight – week to …
3 天之前 · Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure ...
Gilead and Merck tout first weekly oral HIV treatment
2 天之前 · Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor.